Researchers in Australia from RMIT University, in collaboration with the biotech firm Snoretox, have introduced a groundbreaking medication named Snoretox-1, aimed at improving respiratory function in flat-faced dog breeds. Due to selective breeding, breeds such as pugs, French bulldogs, Pekingese, Boston terriers, Shih Tzus, and even Chihuahuas have developed Brachycephalic Obstructive Airway Syndrome (BOAS). This condition results from shortened skull bones and unchanged soft tissue, leading to obstructed airways and chronic breathing difficulties. Statistics reveal that nearly 90% of these breeds experience some form of respiratory issues, with over half suffering from clinically significant conditions. For more than 15 years, researchers have been exploring non-surgical methods to alleviate breathing problems in these breeds, as anesthesia poses additional risks due to their unique anatomy. The newly developed injection utilizes inactivated tetanus toxin and is administered into the geniohyoid muscle, located beneath the throat inside the mouth. This treatment enhances muscle tone and helps maintain open airways. While further trials on a broader range of animals and breeds are necessary before the medication can be commercially available, the initial findings from the research team are encouraging. How can we assist these breeds? Consider supporting treatment options or reevaluating breeding practices.
Informational material. 18+.
